{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:44Z","timestamp":1781654024773,"version":"3.54.5"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.32460174"],"award-info":[{"award-number":["No.32460174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Jiangxi","award":["No.20242BAB26152"],"award-info":[{"award-number":["No.20242BAB26152"]}]},{"name":"Grant of School of Basic Medical Sciences of Nanchang University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00956-2","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:03:16Z","timestamp":1780819396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity of macrophages in PD-1\/PD-L1 inhibitor therapy: a single-cell perspective"],"prefix":"10.1186","volume":"31","author":[{"given":"Jinjing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaqi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daya","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"issue":"8","key":"956_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"956_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002248","volume":"9","author":"E Ahern","year":"2021","unstructured":"Ahern E, Solomon BJ, Hui R, Pavlakis N, O\u2019Byrne K, Hughes BGM. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? J Immunother Cancer. 2021;9(6):e002248.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"956_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.61735","volume":"8","author":"M Lim","year":"2025","unstructured":"Lim M, Espinoza M, Huang YH, Franses J, Zhu H, Hsiehchen D. Complete response to immunotherapy in patients with hepatocellular carcinoma. JAMA Netw Open. 2025;8(2):e2461735.","journal-title":"JAMA Netw Open"},{"key":"956_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X, et\u00a0al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.","journal-title":"Front Immunol"},{"issue":"7","key":"956_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer. 2024;12(7):e008591.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"956_CR6","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon M, An M, Klempner SJ, et\u00a0al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 2021;11(9):2168\u201385.","journal-title":"Cancer Discov"},{"key":"956_CR7","doi-asserted-by":"publisher","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, et\u00a0al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023;14:1295257.","journal-title":"Front Immunol"},{"issue":"7970","key":"956_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41586-023-06386-w","volume":"619","author":"T Lazarov","year":"2023","unstructured":"Lazarov T, Juarez-Carre\u00f1o S, Cox N, Geissmann F. Physiology and diseases of tissue-resident macrophages. Nature. 2023;619(7970):51.","journal-title":"Nature"},{"issue":"1","key":"956_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","volume":"10","author":"F Guan","year":"2025","unstructured":"Guan F, Wang R, Yi Z, et\u00a0al. Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther. 2025;10(1):93.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"956_CR10","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","volume":"14","author":"M Matusiak","year":"2024","unstructured":"Matusiak M, Hickey JW, van IJzendoorn DGP, et\u00a0al. Spatially segregated macrophage populations predict distinct outcomes in colon cancer. Cancer Discov. 2024;14(8):1418\u201339.","journal-title":"Cancer Discov"},{"issue":"7868","key":"956_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes M, Dalla E, Leader AM, et\u00a0al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595(7868):578\u201384.","journal-title":"Nature"},{"issue":"1","key":"956_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49885-8","volume":"15","author":"A Coulton","year":"2024","unstructured":"Coulton A, Murai J, Qian D, Thakkar K, Lewis CE, Litchfield K. Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response. Nat Commun. 2024;15(1):5665.","journal-title":"Nat Commun"},{"issue":"1","key":"956_CR13","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1038\/s41467-023-40271-4","volume":"14","author":"R Arora","year":"2023","unstructured":"Arora R, Cao C, Kumar M, et\u00a0al. Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. Nat Commun. 2023;14(1):5029.","journal-title":"Nat Commun"},{"issue":"6","key":"956_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-022-00632-2","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):424.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"956_CR15","doi-asserted-by":"publisher","first-page":"21608","DOI":"10.1038\/s41598-021-01116-6","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Browne L, Slapetova I, et\u00a0al. Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer. Sci Rep. 2021;11(1):21608.","journal-title":"Sci Rep"},{"key":"956_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001244","author":"K Cheng","year":"2025","unstructured":"Cheng K, Cai N, Yang X, et\u00a0al. Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001244.","journal-title":"Hepatology"},{"issue":"20","key":"956_CR17","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/1759-7714.14108","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Liu H, Zhao Y, et\u00a0al. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). Thorac Cancer. 2021;12(20):2698\u2013709.","journal-title":"Thorac Cancer"},{"issue":"1","key":"956_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, et\u00a0al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):58.","journal-title":"Mol Cancer"},{"issue":"10","key":"956_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70061","volume":"14","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Bei W, Li W, et\u00a0al. Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma. Clin Transl Med. 2024;14(10):e70061.","journal-title":"Clin Transl Med"},{"issue":"1","key":"956_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-024-00605-w","volume":"12","author":"L Dai","year":"2024","unstructured":"Dai L, Fan G, Xie T, et\u00a0al. Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma. Biomark Res. 2024;12(1):58.","journal-title":"Biomark Res"},{"issue":"1","key":"956_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, et\u00a0al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129.","journal-title":"Mol Cancer"},{"issue":"22","key":"956_CR22","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1002\/cncr.33142","volume":"126","author":"H Borghaei","year":"2020","unstructured":"Borghaei H, Langer CJ, Paz-Ares L, et\u00a0al. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867\u201377.","journal-title":"Cancer"},{"issue":"3","key":"956_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"Y Li","year":"2025","unstructured":"Li Y, Zheng Y, Huang J, et\u00a0al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut. 2025;74(3):350\u201363.","journal-title":"Gut"},{"key":"956_CR24","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive biomarkers of immune checkpoint inhibitors-related toxicities. Front Immunol. 2020;11:2023.","journal-title":"Front Immunol"},{"key":"956_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216610","volume":"584","author":"S Yang","year":"2024","unstructured":"Yang S, Wang M, Hua Y, et\u00a0al. Advanced insights on tumor-associated macrophages revealed by single-cell RNA sequencing: the intratumor heterogeneity, functional phenotypes, and cellular interactions. Cancer Lett. 2024;584:216610.","journal-title":"Cancer Lett"},{"issue":"8","key":"956_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","volume":"18","author":"E Barreby","year":"2022","unstructured":"Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD\u2014More than inflammation. Nat Rev Endocrinol. 2022;18(8):461\u201372.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"956_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20209682","volume":"16","author":"H Massalha","year":"2020","unstructured":"Massalha H, Bahar Halpern K, Abu-Gazala S, et\u00a0al. A single cell atlas of the human liver tumor microenvironment. Mol Syst Biol. 2020;16(12):e9682.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"956_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-025-03303-z","volume":"44","author":"Z Pan","year":"2025","unstructured":"Pan Z, Chen J, Xu T, et\u00a0al. VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1. J Exp Clin Cancer Res. 2025;44(1):45.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"956_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu J, Zhang L, Xia H, et\u00a0al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 2023;15(1):14.","journal-title":"Genome Med"},{"issue":"10","key":"956_CR30","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/2159-8290.CD-20-1285","volume":"11","author":"A Sinjab","year":"2021","unstructured":"Sinjab A, Han G, Treekitkarnmongkol W, et\u00a0al. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov. 2021;11(10):2506\u201323.","journal-title":"Cancer Discov"},{"issue":"2","key":"956_CR31","first-page":"180","volume":"22","author":"J Wei","year":"2020","unstructured":"Wei J, Chen P, Gupta P, et\u00a0al. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020;22(2):180\u201394.","journal-title":"Neuro Oncol"},{"issue":"1","key":"956_CR32","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1038\/s41467-024-53659-7","volume":"15","author":"HY Huang","year":"2024","unstructured":"Huang HY, Chen YZ, Zhao C, et\u00a0al. Alternations in inflammatory macrophage niche drive phenotypic and functional plasticity of Kupffer cells. Nat Commun. 2024;15(1):9337.","journal-title":"Nat Commun"},{"issue":"8","key":"956_CR33","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022;23(8):1148\u201356.","journal-title":"Nat Immunol"},{"key":"956_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693517","volume":"11","author":"Y Tan","year":"2021","unstructured":"Tan Y, Wang M, Zhang Y, et\u00a0al. Tumor-associated macrophages: a potential target for cancer therapy. Front Oncol. 2021;11:693517.","journal-title":"Front Oncol"},{"issue":"12","key":"956_CR35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.it.2023.10.007","volume":"44","author":"I Nasir","year":"2023","unstructured":"Nasir I, McGuinness C, Poh AR, Ernst M, Darcy PK, Britt KL. Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies. Trends Immunol. 2023;44(12):971\u201385.","journal-title":"Trends Immunol"},{"issue":"7","key":"956_CR36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"R Nalio Ramos","year":"2022","unstructured":"Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, et\u00a0al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022;185(7):1189-1207.e25.","journal-title":"Cell"},{"issue":"11","key":"956_CR37","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1016\/j.immuni.2024.09.007","volume":"57","author":"JL Ross","year":"2024","unstructured":"Ross JL, Puigdelloses-Vallcorba M, Pi\u00f1ero G, et\u00a0al. Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations. Immunity. 2024;57(11):2669-2687.e6.","journal-title":"Immunity"},{"issue":"1","key":"956_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13059-017-1362-4","volume":"18","author":"S M\u00fcller","year":"2017","unstructured":"M\u00fcller S, Kohanbash G, Liu SJ, et\u00a0al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017;18(1):234.","journal-title":"Genome Biol"},{"issue":"5","key":"956_CR39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","volume":"57","author":"A De Leo","year":"2024","unstructured":"De Leo A, Ugolini A, Yu X, et\u00a0al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. 2024;57(5):1105-1123.e8.","journal-title":"Immunity"},{"issue":"7993","key":"956_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","volume":"625","author":"NM LaMarche","year":"2024","unstructured":"LaMarche NM, Hegde S, Park MD, et\u00a0al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature. 2024;625(7993):166\u201374.","journal-title":"Nature"},{"issue":"7","key":"956_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28332","volume":"10","author":"M Rakina","year":"2024","unstructured":"Rakina M, Larionova I, Kzhyshkowska J. Macrophage diversity in human cancers: new insight provided by single-cell resolution and spatial context. Heliyon. 2024;10(7):e28332.","journal-title":"Heliyon"},{"issue":"3","key":"956_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101340","volume":"12","author":"Z Xie","year":"2024","unstructured":"Xie Z, Zheng G, Niu L, et\u00a0al. SPP1+ macrophages in colorectal cancer: markers of malignancy and promising therapeutic targets. Genes Dis. 2024;12(3):101340.","journal-title":"Genes Dis"},{"issue":"1","key":"956_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13046-024-03255-w","volume":"43","author":"C Liu","year":"2024","unstructured":"Liu C, Wu K, Li C, et\u00a0al. SPP1+ macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-\u03b1 and IL-1\u03b2. J Exp Clin Cancer Res. 2024;43(1):332.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"956_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112131","volume":"42","author":"K Hoeft","year":"2023","unstructured":"Hoeft K, Schaefer GJL, Kim H, et\u00a0al. Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner. Cell Rep. 2023;42(2):112131.","journal-title":"Cell Rep"},{"key":"956_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.749210","volume":"9","author":"J Wei","year":"2021","unstructured":"Wei J, Chen Z, Hu M, et\u00a0al. Characterizing intercellular communication of pan-cancer reveals SPP1+ tumor-associated macrophage expanded in hypoxia and promoting cancer malignancy through single-cell RNA-Seq data. Front Cell Dev Biol. 2021;9:749210.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"956_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-024-01218-4","volume":"14","author":"W Tang","year":"2024","unstructured":"Tang W, Lo CWS, Ma W, Chu ATW, Tong AHY, Chung BHY. Revealing the role of SPP1+ macrophages in glioma prognosis and therapeutic targeting by investigating tumor-associated macrophage landscape in grade 2 and 3 gliomas. Cell Biosci. 2024;14(1):37.","journal-title":"Cell Biosci"},{"key":"956_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961350","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Xu X, Wu Z, et\u00a0al. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS\/TP53 mutation status and tumor-sideness in colorectal cancers. Front Immunol. 2022;13:961350.","journal-title":"Front Immunol"},{"key":"956_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.04.007","author":"K Viiklepp","year":"2025","unstructured":"Viiklepp K, Knuutila JS, Nissinen L, et\u00a0al. Expression of C1q by macrophages and fibroblasts in tumor microenvironment is associated with progression and metastasis of cutaneous squamous cell carcinoma. J Invest Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.04.007.","journal-title":"J Invest Dermatol"},{"key":"956_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264774","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Zhu N, Su X, Gao Y, Yang R. Novel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing. Front Immunol. 2024;14:1264774.","journal-title":"Front Immunol"},{"key":"956_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217062","volume":"597","author":"HR Feng","year":"2024","unstructured":"Feng HR, Shen XN, Zhu XM, et\u00a0al. Unveiling major histocompatibility complex-mediated pan-cancer immune features by integrated single-cell and bulk RNA sequencing. Cancer Lett. 2024;597:217062.","journal-title":"Cancer Lett"},{"key":"956_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.911368","volume":"14","author":"J Tu","year":"2023","unstructured":"Tu J, Wang D, Zheng X, Liu B. Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma. Front Immunol. 2023;14:911368.","journal-title":"Front Immunol"},{"issue":"1","key":"956_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01887-6","volume":"26","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhong F, Liu L. Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer. Breast Cancer Res. 2024;26(1):129.","journal-title":"Breast Cancer Res"},{"key":"956_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694801","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, Zhang Q, Chen G, Luo D. Multi-omics analysis showed the clinical value of gene signatures of C1QC+ and SPP1+ TAMs in cervical cancer. Front Immunol. 2021;12:694801.","journal-title":"Front Immunol"},{"issue":"3","key":"956_CR54","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","volume":"178","author":"DA Jaitin","year":"2019","unstructured":"Jaitin DA, Adlung L, Thaiss CA, et\u00a0al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell. 2019;178(3):686-698.e14.","journal-title":"Cell"},{"issue":"10","key":"956_CR55","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00262-022-03173-w","volume":"71","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu Z, Wen H, et\u00a0al. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer Immunol Immunother. 2022;71(10):2511\u201322.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"956_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03287-w","volume":"44","author":"H Guo","year":"2025","unstructured":"Guo H, Wang M, Ni C, et\u00a0al. TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44(1):20.","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"956_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413019","volume":"12","author":"G Zhang","year":"2025","unstructured":"Zhang G, Zhang X, Pan W, et\u00a0al. Dissecting the spatial and single-cell transcriptomic architecture of cancer stem cell niche driving tumor progression in gastric cancer. Adv Sci (Weinh). 2025;12(18):e2413019.","journal-title":"Adv Sci (Weinh)"},{"issue":"7986","key":"956_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni N, La Terza F, Vittoria FM, et\u00a0al. IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623(7986):415\u201322.","journal-title":"Nature"},{"issue":"5","key":"956_CR59","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/cac2.12420","volume":"43","author":"Z Wen","year":"2023","unstructured":"Wen Z, Sun H, Zhang Z, et\u00a0al. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Cancer Commun (Lond). 2023;43(5):562\u201381.","journal-title":"Cancer Commun (Lond)"},{"key":"956_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679928","volume":"11","author":"LR Jiang","year":"2021","unstructured":"Jiang LR, Zhang N, Chen ST, et\u00a0al. PD-1-positive tumor-associated macrophages define poor clinical outcomes in patients with muscle invasive bladder cancer through potential CD68\/PD-1 complex interactions. Front Oncol. 2021;11:679928.","journal-title":"Front Oncol"},{"issue":"17","key":"956_CR61","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-24-0942","volume":"30","author":"M Pourmaleki","year":"2024","unstructured":"Pourmaleki M, Jones CJ, Mellinghoff SD, et\u00a0al. Multiplexed spatial profiling of hodgkin reed-sternberg cell neighborhoods in classic hodgkin lymphoma. Clin Cancer Res. 2024;30(17):3881\u201393.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"956_CR62","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43(7):546\u201363.","journal-title":"Trends Immunol"},{"issue":"5","key":"956_CR63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","volume":"42","author":"W Wang","year":"2024","unstructured":"Wang W, Li T, Cheng Y, et\u00a0al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell. 2024;42(5):815-832.e12.","journal-title":"Cancer Cell"},{"issue":"1","key":"956_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12967-024-04848-x","volume":"22","author":"G Yang","year":"2024","unstructured":"Yang G, Cheng J, Xu J, et\u00a0al. Metabolic heterogeneity in clear cell renal cell carcinoma revealed by single-cell RNA sequencing and spatial transcriptomics. J Transl Med. 2024;22(1):210.","journal-title":"J Transl Med"},{"key":"956_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1612262","volume":"16","author":"W Cao","year":"2026","unstructured":"Cao W, Zhuang W, Xu K. Integrated multi-omic profiling reveals macrophage-driven prognostic signatures in clear cell renal cell carcinoma through machine learning optimization. Front Immunol. 2026;16:1612262. https:\/\/doi.org\/10.3389\/fimmu.2025.1612262.","journal-title":"Front Immunol"},{"issue":"1","key":"956_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110609","volume":"39","author":"S Li","year":"2022","unstructured":"Li S, Yu J, Huber A, et\u00a0al. Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Rep. 2022;39(1):110609.","journal-title":"Cell Rep"},{"issue":"6739","key":"956_CR67","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.adw1956","volume":"387","author":"E Jacinto","year":"2025","unstructured":"Jacinto E. Making sense of fat in cancer. Science. 2025;387(6739):1147\u20138.","journal-title":"Science"},{"issue":"4","key":"956_CR68","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2024.09.029","volume":"82","author":"X Yang","year":"2025","unstructured":"Yang X, Deng B, Zhao W, et\u00a0al. FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity. J Hepatol. 2025;82(4):676\u201389.","journal-title":"J Hepatol"},{"issue":"3","key":"956_CR69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2520427123","volume":"123","author":"L Tan","year":"2026","unstructured":"Tan L, Zhou H, Zhang B, et\u00a0al. Multiomics identifies a cholesterol-TFEB-PLD3-TLR9 axis driving immunosuppressive tumor-associated macrophage polarization in esophageal squamous cell carcinoma. Proc Natl Acad Sci USA. 2026;123(3):e2520427123. https:\/\/doi.org\/10.1073\/pnas.2520427123.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"956_CR70","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1021\/acs.jmedchem.5c00026","volume":"68","author":"PJ Monsen","year":"2025","unstructured":"Monsen PJ, Bommi PV, Grigorescu AA, et\u00a0al. Rational design and optimization of a potent ido1 proteolysis targeting chimera (PROTAC). J Med Chem. 2025;68(4):4961\u201387.","journal-title":"J Med Chem"},{"key":"956_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101272","author":"W Ding","year":"2025","unstructured":"Ding W, Mo J, Su Y, et\u00a0al. Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer. Drug Resist Update. 2025. https:\/\/doi.org\/10.1016\/j.drup.2025.101272.","journal-title":"Drug Resist Update"},{"issue":"12","key":"956_CR72","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.7150\/thno.99112","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang J, Zhao S, et\u00a0al. Single-cell RNA sequencing highlights the immunosuppression of IDO1+ macrophages in the malignant transformation of oral leukoplakia. Theranostics. 2024;14(12):4787\u2013805.","journal-title":"Theranostics"},{"key":"956_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2025.09.007","volume":"117","author":"MC Martinez-Campanario","year":"2025","unstructured":"Martinez-Campanario MC, Cort\u00e9s M, Han L, et\u00a0al. Lipid-laden macrophages in atherosclerosis and cancer. Semin Cancer Biol. 2025;117:38\u201356. https:\/\/doi.org\/10.1016\/j.semcancer.2025.09.007.","journal-title":"Semin Cancer Biol"},{"key":"956_CR74","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","volume":"11","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, et\u00a0al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731.","journal-title":"Front Immunol"},{"issue":"1","key":"956_CR75","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","volume":"57","author":"Y Yan","year":"2025","unstructured":"Yan Y, Sun D, Hu J, et\u00a0al. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat Genet. 2025;57(1):126\u201339.","journal-title":"Nat Genet"},{"issue":"1","key":"956_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111929","volume":"42","author":"Y Ozato","year":"2023","unstructured":"Ozato Y, Kojima Y, Kobayashi Y, et\u00a0al. Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. Cell Rep. 2023;42(1):111929.","journal-title":"Cell Rep"},{"issue":"6","key":"956_CR77","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41588-025-02193-3","volume":"57","author":"MF Oliveira","year":"2025","unstructured":"Oliveira MF, Romero JP, Chung M, et\u00a0al. High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer. Nat Genet. 2025;57(6):1512\u201323.","journal-title":"Nat Genet"},{"issue":"1","key":"956_CR78","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41467-025-60028-5","volume":"16","author":"W Su","year":"2025","unstructured":"Su W, Ye Z, Liu J, et\u00a0al. Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression. Nat Commun. 2025;16(1):5007.","journal-title":"Nat Commun"},{"issue":"2","key":"956_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14020294","volume":"14","author":"F Li","year":"2026","unstructured":"Li F, Xu D, Tang Z, et\u00a0al. SPP1+ macrophages and the orchestration of spatially organized immunosuppression in cancer. Biomedicines. 2026;14(2):294. https:\/\/doi.org\/10.3390\/biomedicines14020294.","journal-title":"Biomedicines"},{"issue":"17","key":"956_CR80","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","volume":"186","author":"B Ruf","year":"2023","unstructured":"Ruf B, Bruhns M, Babaei S, et\u00a0al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell. 2023;186(17):3686-3705.e32.","journal-title":"Cell"},{"issue":"5","key":"956_CR81","doi-asserted-by":"publisher","first-page":"984","DOI":"10.7150\/ijbs.29836","volume":"15","author":"C Yang","year":"2019","unstructured":"Yang C, Wei C, Wang S, et\u00a0al. Elevated CD163+\/CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer. Int J Biol Sci. 2019;15(5):984\u201398.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"956_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-026-07853-4","volume":"24","author":"S Xie","year":"2026","unstructured":"Xie S, Li J, Heng S, Xiao J, Chen J, Qi X. Integrated single-cell and spatial transcriptomics uncover SPP1\u207a and HLA-DRB5\u207a macrophages as key modulators of the immune microenvironment in colorectal cancer liver metastasis. J Transl Med. 2026;24(1):370. https:\/\/doi.org\/10.1186\/s12967-026-07853-4.","journal-title":"J Transl Med"},{"issue":"1","key":"956_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07581-1","volume":"24","author":"X Qi","year":"2025","unstructured":"Qi X, Hou S, Xie S, Chen J. Integrative single-cell and spatial transcriptomic analysis reveals lipid metabolism-mediated macrophage heterogeneity during colorectal cancer liver metastasis progression. J Transl Med. 2025;24(1):117. https:\/\/doi.org\/10.1186\/s12967-025-07581-1.","journal-title":"J Transl Med"},{"issue":"1","key":"956_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01974-8","volume":"26","author":"S Shen","year":"2025","unstructured":"Shen S, Li Z, Yang H, Zhang X, Chen G, Pa C. Single-cell transcriptomic analysis reveals key cell types and pathogenic genes associated with metastasis in pancreatic adenocarcinoma. Clin Exp Med. 2025;26(1):61. https:\/\/doi.org\/10.1007\/s10238-025-01974-8.","journal-title":"Clin Exp Med"},{"key":"956_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0819","author":"GJ Herrera","year":"2024","unstructured":"Herrera GJ, Sun L, Lee AH, Everson RG, Nathanson DA, Liau LM, et\u00a0al. 819. Temporal influence of PD-1 blockade after vaccination on macrophage-driven CD8+ T cell exhaustion within the glioblastoma microenvironment. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0819.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"956_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009024","volume":"12","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang B, Feng Y, et al. Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. J Immunother Cancer. 2024;12(8):e009024. https:\/\/doi.org\/10.1136\/jitc-2024-009024. (Published 2024 Aug 6).","journal-title":"J Immunother Cancer"},{"issue":"1","key":"956_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010683","volume":"13","author":"R Leshem","year":"2025","unstructured":"Leshem R, Sefton KN, Wong CW, et al. Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma. J Immunother Cancer. 2025;13(1):e010683. https:\/\/doi.org\/10.1136\/jitc-2024-010683. (Published 2025 Jan 27).","journal-title":"J Immunother Cancer"},{"issue":"1","key":"956_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06186-y","volume":"23","author":"VY Naei","year":"2025","unstructured":"Naei VY, Tubelleza R, Monkman J, et al. Spatial interaction mapping of PD-1\/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response. J Transl Med. 2025;23(1):177. https:\/\/doi.org\/10.1186\/s12967-025-06186-y. (Published 2025 Feb 12).","journal-title":"J Transl Med"},{"issue":"1","key":"956_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05035-8","volume":"22","author":"J Monkman","year":"2024","unstructured":"Monkman J, Moradi A, Yunis J, et al. Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging. J Transl Med. 2024;22(1):239. https:\/\/doi.org\/10.1186\/s12967-024-05035-8. (Published 2024 Mar 4).","journal-title":"J Transl Med"},{"issue":"6","key":"956_CR90","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas MJ, Middelburg J, Labrie C, et\u00a0al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42(6):1032-1050.e10.","journal-title":"Cancer Cell"},{"issue":"7","key":"956_CR91","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, Mittman S, Rodriguez R, et\u00a0al. Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 2019;79(7):1493\u2013506.","journal-title":"Cancer Res"},{"issue":"5","key":"956_CR92","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cell.2018.11.003","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin MM, Esaulova E, Ward JP, et\u00a0al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175(5):1443.","journal-title":"Cell"},{"issue":"9","key":"956_CR93","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.neo.2019.07.006","volume":"21","author":"E Fiegle","year":"2019","unstructured":"Fiegle E, Doleschel D, Koletnik S, et\u00a0al. Dual CTLA-4 and PD-L1 blockade inhibits tumor growth and liver metastasis in a highly aggressive orthotopic mouse model of colon cancer. Neoplasia. 2019;21(9):932\u201344.","journal-title":"Neoplasia"},{"issue":"10","key":"956_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007305","volume":"11","author":"M Chen","year":"2023","unstructured":"Chen M, Ma P, Zhang Y, et\u00a0al. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma. J Immunother Cancer. 2023;11(10):e007305.","journal-title":"J Immunother Cancer"},{"issue":"7655","key":"956_CR95","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, et\u00a0al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature"},{"issue":"1","key":"956_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, et\u00a0al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"956_CR97","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez A, Vos H, Van Dyck L, et\u00a0al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27(5):820\u201332.","journal-title":"Nat Med"},{"issue":"2","key":"956_CR98","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, et\u00a0al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"956_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108115","volume":"32","author":"Y Qu","year":"2020","unstructured":"Qu Y, Wen J, Thomas G, et\u00a0al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to Avelumab treatment. Cell Rep. 2020;32(9):108115.","journal-title":"Cell Rep"},{"issue":"6","key":"956_CR100","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm AJ, et\u00a0al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885-900.e10.","journal-title":"Cancer Cell"},{"issue":"1","key":"956_CR101","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et\u00a0al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"956_CR102","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s41467-024-46195-x","volume":"15","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zhou X, Jiang X, et\u00a0al. Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis. Nat Commun. 2024;15(1):2107.","journal-title":"Nat Commun"},{"issue":"9","key":"956_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005323","volume":"10","author":"A Franken","year":"2022","unstructured":"Franken A, Van Mol P, Vanmassenhove S, et\u00a0al. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. J Immunother Cancer. 2022;10(9):e005323.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"956_CR104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.123.067189","volume":"149","author":"D \u010cih\u00e1kov\u00e1","year":"2024","unstructured":"\u010cih\u00e1kov\u00e1 D. T cells and macrophages drive pathogenesis of immune checkpoint inhibitor myocarditis. Circulation. 2024;149(1):67\u20139.","journal-title":"Circulation"},{"issue":"5","key":"956_CR105","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, et\u00a0al. Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC CardioOncol. 2022;4(5):689\u2013700.","journal-title":"JACC CardioOncol"},{"issue":"18","key":"956_CR106","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et\u00a0al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"956_CR107","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei SC, Meijers WC, Axelrod ML, et\u00a0al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021;11(3):614\u201325.","journal-title":"Cancer Discov"},{"issue":"11","key":"956_CR108","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann LH, Cautela J, Palaskas N, et\u00a0al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 2021;6(11):1329\u201337.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"956_CR109","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu H, Galdos FX, Lee D, et\u00a0al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation. 2022;146(4):316\u201335.","journal-title":"Circulation"},{"issue":"8041","key":"956_CR110","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","volume":"636","author":"SM Blum","year":"2024","unstructured":"Blum SM, Zlotoff DA, Smith NP, et\u00a0al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature. 2024;636(8041):215\u201323.","journal-title":"Nature"},{"issue":"1","key":"956_CR111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","volume":"33","author":"SN Champion","year":"2020","unstructured":"Champion SN, Stone JR. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol. 2020;33(1):99\u2013108.","journal-title":"Mod Pathol"},{"issue":"1","key":"956_CR112","first-page":"14","volume":"9","author":"J Jimenez","year":"2023","unstructured":"Jimenez J, Kostelecky N, Mitchell JD, et\u00a0al. Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. Cardiooncology. 2023;9(1):14.","journal-title":"Cardiooncology"},{"issue":"1","key":"956_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00395-024-01070-0","volume":"120","author":"F Buehning","year":"2025","unstructured":"Buehning F, Lerchner T, Vogel J, et\u00a0al. Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Basic Res Cardiol. 2025;120(1):171\u201385.","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"956_CR114","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma P, Liu J, Qin J, et\u00a0al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation. 2024;149(1):48\u201366.","journal-title":"Circulation"},{"issue":"7","key":"956_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02778-2","volume":"11","author":"W Xia","year":"2020","unstructured":"Xia W, Zou C, Chen H, Xie C, Hou M. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling. Cell Death Dis. 2020;11(7):575.","journal-title":"Cell Death Dis"},{"issue":"2","key":"956_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001293","volume":"8","author":"W Xia","year":"2020","unstructured":"Xia W, Chen H, Chen D, Ye Y, Xie C, Hou M. PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction. J Immunother Cancer. 2020;8(2):e001293.","journal-title":"J Immunother Cancer"},{"key":"956_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114263","volume":"150","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Cao Z, Jia H, et\u00a0al. Immune checkpoint inhibitor induces cardiac injury by impairing efferocytosis of macrophages via MerTK cleavage. Int Immunopharmacol. 2025;150:114263.","journal-title":"Int Immunopharmacol"},{"key":"956_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156873","volume":"187","author":"Z Cao","year":"2025","unstructured":"Cao Z, Zhang Y, Jia H, et\u00a0al. Immune checkpoint inhibitors mediate myocarditis by promoting macrophage polarization via cGAS\/STING pathway. Cytokine. 2025;187:156873.","journal-title":"Cytokine"},{"issue":"1","key":"956_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02201-4","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen Y, Liu Y, Wang Y, et\u00a0al. Prevotellaceae produces butyrate to alleviate PD-1\/PD-L1 inhibitor-related cardiotoxicity via PPAR\u03b1-CYP4X1 axis in colonic macrophages. J Exp Clin Cancer Res. 2022;41(1):1.","journal-title":"J Exp Clin Cancer Res"},{"key":"956_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114676","volume":"156","author":"X He","year":"2025","unstructured":"He X, Zhang J, Zhang Y, et\u00a0al. L-Kynurenine regulates immune response in ICIs-associated myocarditis via JAK\/STAT pathway. Int Immunopharmacol. 2025;156:114676.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"956_CR121","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-024-01979-1","volume":"74","author":"Y Chen","year":"2025","unstructured":"Chen Y, Luo Y, Liu Y, Qiu X, Luo D, Liu A. Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury. Inflamm Res. 2025;74(1):56.","journal-title":"Inflamm Res"},{"issue":"12","key":"956_CR122","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et\u00a0al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1792.","journal-title":"JAMA Oncol"},{"issue":"10","key":"956_CR123","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/PAS.0000000000001298","volume":"43","author":"BT Larsen","year":"2019","unstructured":"Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC. Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol. 2019;43(10):1331\u201340.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"956_CR124","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41698-024-00715-6","volume":"8","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Zhang L, Wang K, et\u00a0al. Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis. NPJ Precis Oncol. 2024;8(1):226.","journal-title":"NPJ Precis Oncol"},{"issue":"42","key":"956_CR125","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1038\/s41388-023-02805-4","volume":"42","author":"P Cui","year":"2023","unstructured":"Cui P, Li J, Tao H, et\u00a0al. Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis. Oncogene. 2023;42(42):3098\u2013112.","journal-title":"Oncogene"},{"issue":"4","key":"956_CR126","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00262-025-03983-8","volume":"74","author":"L Zheng","year":"2025","unstructured":"Zheng L, Lin F, Cai D, et\u00a0al. Single-cell transcriptome sequencing reveals the immune microenvironment in bronchoalveolar lavage fluid of checkpoint inhibitor-related pneumonitis. Cancer Immunol Immunother. 2025;74(4):128.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"956_CR127","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41419-024-06535-7","volume":"15","author":"L Shojaie","year":"2024","unstructured":"Shojaie L, Bogdanov JM, Alavifard H, et\u00a0al. Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis. 2024;15(2):140.","journal-title":"Cell Death Dis"},{"issue":"1","key":"956_CR128","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","volume":"75","author":"CLC Gudd","year":"2021","unstructured":"Gudd CLC, Au L, Triantafyllou E, et\u00a0al. Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. J Hepatol. 2021;75(1):177\u201389.","journal-title":"J Hepatol"},{"issue":"4","key":"956_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008078","volume":"12","author":"CLC Gudd","year":"2024","unstructured":"Gudd CLC, Mitchell E, Atkinson SR, et\u00a0al. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis. J Immunother Cancer. 2024;12(4):e008078.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"956_CR130","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41575-024-01019-7","volume":"22","author":"E Triantafyllou","year":"2025","unstructured":"Triantafyllou E, Gudd CLC, Possamai LA. Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management. Nat Rev Gastroenterol Hepatol. 2025;22(2):112\u201326.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"956_CR131","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jhep.2021.06.037","volume":"75","author":"HP Llewellyn","year":"2021","unstructured":"Llewellyn HP, Arat S, Gao J, et\u00a0al. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model. J Hepatol. 2021;75(5):1083\u201395.","journal-title":"J Hepatol"},{"issue":"751","key":"956_CR132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9672","volume":"16","author":"JM Vinnakota","year":"2024","unstructured":"Vinnakota JM, Adams RC, Athanassopoulos D, et\u00a0al. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation. Sci Transl Med. 2024;16(751):eadj9672.","journal-title":"Sci Transl Med"},{"issue":"4","key":"956_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100683","volume":"38","author":"U Maccio","year":"2025","unstructured":"Maccio U, Wicki A, Ruschitzka F, et\u00a0al. Frequency and consequences of immune checkpoint inhibitor-associated inflammatory changes in different organs: an autopsy study over 13-years. Mod Pathol. 2025;38(4):100683.","journal-title":"Mod Pathol"},{"issue":"1","key":"956_CR134","doi-asserted-by":"publisher","first-page":"10733","DOI":"10.1038\/s41467-024-54180-7","volume":"15","author":"CB Chen","year":"2024","unstructured":"Chen CB, Hung SI, Chang JW, et\u00a0al. Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade. Nat Commun. 2024;15(1):10733.","journal-title":"Nat Commun"},{"key":"956_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG, et\u00a0al. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024;15:1447021.","journal-title":"Front Immunol"},{"issue":"6","key":"956_CR136","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","volume":"66","author":"MS von Itzstein","year":"2020","unstructured":"von Itzstein MS, Khan S, Gerber DE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem. 2020;66(6):779\u201393.","journal-title":"Clin Chem"},{"issue":"1","key":"956_CR137","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","volume":"5","author":"TE Angell","year":"2018","unstructured":"Angell TE, Min L, Wieczorek TJ, Hodi FS. Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. Genes Dis. 2018;5(1):46\u20138.","journal-title":"Genes Dis"},{"issue":"5","key":"956_CR138","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccell.2024.04.010","volume":"42","author":"T Gupta","year":"2024","unstructured":"Gupta T, Antanaviciute A, Hyun-Jung Lee C, et\u00a0al. Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis. Cancer Cell. 2024;42(5):797-814.e15.","journal-title":"Cancer Cell"},{"issue":"9","key":"956_CR139","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, et\u00a0al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278\u201385.","journal-title":"Nat Med"},{"issue":"5","key":"956_CR140","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","volume":"8","author":"G Chen","year":"2023","unstructured":"Chen G, Jin Y, Guan WL, et\u00a0al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8(5):422\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"956_CR141","doi-asserted-by":"publisher","first-page":"1708065","DOI":"10.1080\/2162402X.2019.1708065","volume":"9","author":"S Kato","year":"2020","unstructured":"Kato S, Okamura R, Kumaki Y, et\u00a0al. Expression of TIM3\/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1\/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020;9(1):1708065.","journal-title":"Oncoimmunology"},{"issue":"11","key":"956_CR142","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, et\u00a0al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun (Lond). 2024;44(11):1231\u201360.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"956_CR143","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12943-024-02092-x","volume":"23","author":"S Cousin","year":"2024","unstructured":"Cousin S, Gu\u00e9gan JP, Shitara K, et\u00a0al. Identification of microenvironment features associated with primary resistance to anti-PD-1\/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics. Mol Cancer. 2024;23(1):197.","journal-title":"Mol Cancer"},{"issue":"2","key":"956_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010826","volume":"13","author":"Y Chen","year":"2025","unstructured":"Chen Y, Jia H, Zhang X, et\u00a0al. Disruption of GPSM1\/CSF1 signaling reprograms tumor-associated macrophages to overcome anti-PD-1 resistance in colorectal cancer. J Immunother Cancer. 2025;13(2):e010826.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"956_CR145","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.1038\/s41598-025-91979-w","volume":"15","author":"H Inoue","year":"2025","unstructured":"Inoue H, Hamasaki T, Inoue K, et\u00a0al. Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model. Sci Rep. 2025;15(1):8311.","journal-title":"Sci Rep"},{"issue":"1","key":"956_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101262","volume":"15","author":"J Zhou","year":"2022","unstructured":"Zhou J, Jiang Y, Huang Y, et\u00a0al. Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Transl Oncol. 2022;15(1):101262.","journal-title":"Transl Oncol"},{"issue":"10","key":"956_CR147","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1084\/jem.20182124","volume":"216","author":"A Etzerodt","year":"2019","unstructured":"Etzerodt A, Tsalkitzi K, Maniecki M, et\u00a0al. Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. J Exp Med. 2019;216(10):2394\u2013411.","journal-title":"J Exp Med"},{"issue":"4","key":"956_CR148","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jhep.2022.11.004","volume":"78","author":"CY Wei","year":"2023","unstructured":"Wei CY, Zhu MX, Zhang PF, et\u00a0al. PKC\u03b1\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2023;78(4):881\u20132.","journal-title":"J Hepatol"},{"issue":"1","key":"956_CR149","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41467-025-56714-z","volume":"16","author":"W Jiang","year":"2025","unstructured":"Jiang W, Guan B, Sun H, et\u00a0al. WNT11 promotes immune evasion and resistance to anti-PD-1 therapy in liver metastasis. Nat Commun. 2025;16(1):1429.","journal-title":"Nat Commun"},{"issue":"1","key":"956_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02110-w","volume":"10","author":"M Rausch","year":"2025","unstructured":"Rausch M, Bartels K, Leibold J. Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanisms. Signal Transduct Target Ther. 2025;10(1):17. https:\/\/doi.org\/10.1038\/s41392-024-02110-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"956_CR151","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, et\u00a0al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA. 2018;115(17):E4041\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"956_CR152","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","volume":"78","author":"V Quaranta","year":"2018","unstructured":"Quaranta V, Rainer C, Nielsen SR, et\u00a0al. Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer. Cancer Res. 2018;78(15):4253\u201369.","journal-title":"Cancer Res"},{"issue":"1","key":"956_CR153","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde M, Penel N, Adam J, et\u00a0al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93\u20137.","journal-title":"JAMA Oncol"},{"key":"956_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression. Front Immunol. 2022;13:874589.","journal-title":"Front Immunol"},{"issue":"389","key":"956_CR155","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas SP, Garris CS, Kohler RH, et\u00a0al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017;9(389):eaal3604.","journal-title":"Sci Transl Med"},{"issue":"3","key":"956_CR156","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, et\u00a0al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res. 2019;25(3):989\u201399.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"956_CR157","doi-asserted-by":"publisher","first-page":"2063225","DOI":"10.1080\/2162402X.2022.2063225","volume":"11","author":"K Kos","year":"2022","unstructured":"Kos K, Salvagno C, Wellenstein MD, et\u00a0al. Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling. Oncoimmunology. 2022;11(1):2063225.","journal-title":"Oncoimmunology"},{"key":"956_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690869","volume":"12","author":"H Cai","year":"2021","unstructured":"Cai H, Zhang Y, Wang J, Gu J. Defects in macrophage reprogramming in cancer therapy: the negative impact of PD-L1\/PD-1. Front Immunol. 2021;12:690869.","journal-title":"Front Immunol"},{"issue":"1","key":"956_CR159","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee AH, Sun L, Mochizuki AY, et\u00a0al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021;12(1):6938.","journal-title":"Nat Commun"},{"issue":"10","key":"956_CR160","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/0008-5472.CAN-24-2982","volume":"85","author":"X Yang","year":"2025","unstructured":"Yang X, Deng Y, Ye Y, et\u00a0al. Macrophage-derived itaconate suppresses dendritic cell function to promote acquired resistance to anti-PD-1 immunotherapy. Cancer Res. 2025;85(10):1842\u201356.","journal-title":"Cancer Res"},{"issue":"1","key":"956_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02651-9","volume":"23","author":"Y Shi","year":"2022","unstructured":"Shi Y, Zhang Q, Bi H, et\u00a0al. Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing. Genome Biol. 2022;23(1):87.","journal-title":"Genome Biol"},{"issue":"1","key":"956_CR162","doi-asserted-by":"publisher","first-page":"10740","DOI":"10.1038\/s41467-024-54512-7","volume":"15","author":"J Paczkowska","year":"2024","unstructured":"Paczkowska J, Tang M, Wright KT, et\u00a0al. Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma. Nat Commun. 2024;15(1):10740.","journal-title":"Nat Commun"},{"issue":"10","key":"956_CR163","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-24-3135","volume":"31","author":"W Zhang","year":"2025","unstructured":"Zhang W, Li JB, Liu HM, et\u00a0al. PERK+ macrophages drive immunotherapy resistance in lymph node metastases of oral squamous cell carcinoma. Clin Cancer Res. 2025;31(10):1894\u2013911.","journal-title":"Clin Cancer Res"},{"key":"956_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111818","volume":"131","author":"K Chang","year":"2024","unstructured":"Chang K, Jiao Y, Zhang B, et\u00a0al. MGP+ and IDO1+ tumor-associated macrophages facilitate immunoresistance in breast cancer revealed by single-cell RNA sequencing. Int Immunopharmacol. 2024;131:111818.","journal-title":"Int Immunopharmacol"},{"issue":"23","key":"956_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401061","volume":"11","author":"C Liu","year":"2024","unstructured":"Liu C, Xie J, Lin B, et\u00a0al. Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy. Adv Sci (Weinh). 2024;11(23):e2401061.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"956_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou Y, Ye F, Kong Y, et\u00a0al. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh). 2023;10(5):e2203699.","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"956_CR167","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s43018-024-00771-8","volume":"5","author":"T Scolaro","year":"2024","unstructured":"Scolaro T, Manco M, Pecqueux M, et\u00a0al. Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance. Nat Cancer. 2024;5(8):1206\u201326.","journal-title":"Nat Cancer"},{"key":"956_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03425-w","author":"L You","year":"2025","unstructured":"You L, Wang Q, Zhang T, et\u00a0al. USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells. Oncogene. 2025. https:\/\/doi.org\/10.1038\/s41388-025-03425-w.","journal-title":"Oncogene"},{"issue":"7","key":"956_CR169","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ccell.2021.05.006","volume":"39","author":"A Chow","year":"2021","unstructured":"Chow A, Schad S, Green MD, et\u00a0al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell. 2021;39(7):973-988.e9.","journal-title":"Cancer Cell"},{"issue":"Pt 3","key":"956_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.142415","volume":"308","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Y, Fang H, et\u00a0al. Single-cell and spatial analyses reveal the effect of VSIG4+S100A10+TAMs on the immunosuppression of glioblastoma and anti-PD-1 immunotherapy. Int J Biol Macromol. 2025;308(Pt 3):142415.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"956_CR171","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-024-03124-6","volume":"43","author":"Q Wang","year":"2024","unstructured":"Wang Q, Wu Y, Jiang G, Huang X. Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer. J Exp Clin Cancer Res. 2024;43(1):224.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"956_CR172","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1038\/s41467-020-18546-x","volume":"11","author":"D Xiong","year":"2020","unstructured":"Xiong D, Wang Y, You M. A gene expression signature of TREM2hi macrophages and \u03b3\u03b4 T cells predicts immunotherapy response. Nat Commun. 2020;11(1):5084.","journal-title":"Nat Commun"},{"issue":"4","key":"956_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1011235","volume":"20","author":"L Xu","year":"2024","unstructured":"Xu L, Chen Y, Liu L, et\u00a0al. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages. PLoS Genet. 2024;20(4):e1011235.","journal-title":"PLoS Genet"},{"key":"956_CR174","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70016","author":"R Zhao","year":"2025","unstructured":"Zhao R, Pan Z, Qiu J, et\u00a0al. Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages. Cancer Commun (Lond). 2025. https:\/\/doi.org\/10.1002\/cac2.70016.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"956_CR175","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tian H, Chen X, et\u00a0al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 2024;15(1):9097.","journal-title":"Nat Commun"},{"key":"956_CR176","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-24-0791","author":"S Mei","year":"2025","unstructured":"Mei S, Zhang H, Hirz T, et\u00a0al. Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis. Mol Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1541-7786.MCR-24-0791.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"956_CR177","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, et\u00a0al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742.","journal-title":"Nat Commun"},{"issue":"4","key":"956_CR178","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, et\u00a0al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770\u201382.","journal-title":"J Hepatol"},{"issue":"6657","key":"956_CR179","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R, Wirapati P, Messemaker M, et\u00a0al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515\u201324.","journal-title":"Science"},{"issue":"1","key":"956_CR180","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymthe.2018.11.010","volume":"27","author":"G Shi","year":"2019","unstructured":"Shi G, Yang Q, Zhang Y, et\u00a0al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther. 2019;27(1):244\u201360.","journal-title":"Mol Ther"},{"issue":"7","key":"956_CR181","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","volume":"5","author":"F Dammeijer","year":"2017","unstructured":"Dammeijer F, Lievense LA, Kaijen-Lambers ME, et\u00a0al. Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol Res. 2017;5(7):535\u201346.","journal-title":"Cancer Immunol Res"},{"key":"956_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122815","volume":"314","author":"N Liu","year":"2025","unstructured":"Liu N, Yan M, Lu C, et\u00a0al. Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1\/CCL5 mediated M1 macrophage polarization in melanoma. Biomaterials. 2025;314:122815.","journal-title":"Biomaterials"},{"issue":"1","key":"956_CR183","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41467-020-20723-x","volume":"12","author":"Z Wei","year":"2021","unstructured":"Wei Z, Zhang X, Yong T, et\u00a0al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat Commun. 2021;12(1):440.","journal-title":"Nat Commun"},{"issue":"4","key":"956_CR184","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/CIRCRESAHA.115.306256","volume":"118","author":"I Tabas","year":"2016","unstructured":"Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016;118(4):653\u201367.","journal-title":"Circ Res"},{"issue":"1","key":"956_CR185","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Per\u00e1n M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17(1):44.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"956_CR186","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004863","volume":"10","author":"S Peters","year":"2022","unstructured":"Peters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. J Immunother Cancer. 2022;10(7):e004863.","journal-title":"J Immunother Cancer"},{"issue":"8048","key":"956_CR187","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, et\u00a0al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637(8048):1207\u201317.","journal-title":"Nature"},{"issue":"3","key":"956_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109844","volume":"37","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, et\u00a0al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021;37(3):109844.","journal-title":"Cell Rep"},{"issue":"95","key":"956_CR189","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi5374","volume":"9","author":"B Di Luccia","year":"2024","unstructured":"Di Luccia B, Molgora M, Khantakova D, et\u00a0al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy. Sci Immunol. 2024;9(95):eadi5374.","journal-title":"Sci Immunol"},{"issue":"1","key":"956_CR190","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","volume":"46","author":"R Reschke","year":"2025","unstructured":"Reschke R, Sullivan RJ, Lipson EJ, Enk AH, Gajewski TF, Hassel JC. Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025;46(1):61\u201373.","journal-title":"Trends Immunol"},{"issue":"2","key":"956_CR191","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00262-024-03899-9","volume":"74","author":"Y Chen","year":"2025","unstructured":"Chen Y, Luo Y, Liu Y, Luo D, Liu A. Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study. Cancer Immunol Immunother. 2025;74(2):52.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"956_CR192","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","volume":"136","author":"YV Huang","year":"2025","unstructured":"Huang YV, Sun Y, Chou H, et\u00a0al. Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis. Circ Res. 2025;136(5):473\u201390.","journal-title":"Circ Res"},{"key":"956_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156620","volume":"179","author":"X Wang","year":"2024","unstructured":"Wang X, Chen J, Shen Y, et\u00a0al. Baricitinib protects ICIs-related myocarditis by targeting JAK1\/STAT3 to regulate macrophage polarization. Cytokine. 2024;179:156620.","journal-title":"Cytokine"},{"issue":"3","key":"956_CR194","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma AM, Suo S, Williams HL, et\u00a0al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-671.e22.","journal-title":"Cell"},{"issue":"7756","key":"956_CR195","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz E, Minute L, Otano I, et\u00a0al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428\u201332.","journal-title":"Nature"},{"issue":"1","key":"956_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0711-0","volume":"7","author":"YR Badran","year":"2019","unstructured":"Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7(1):226 (Published 2019 Aug 22).","journal-title":"J Immunother Cancer"},{"issue":"44","key":"956_CR197","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202410340","volume":"36","author":"S Moon","year":"2024","unstructured":"Moon S, Jung M, Go S, et\u00a0al. Engineered nanoparticles for enhanced antitumoral synergy between macrophages and T cells in the tumor microenvironment. Adv Mater. 2024;36(44):e2410340.","journal-title":"Adv Mater"},{"issue":"29","key":"956_CR198","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308325","volume":"11","author":"R Han","year":"2024","unstructured":"Han R, Ren Z, Wang Q, et\u00a0al. Synthetic biomimetic liposomes harness efferocytosis machinery for highly efficient macrophages-targeted drug delivery to alleviate inflammation. Adv Sci (Weinh). 2024;11(29):e2308325.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"956_CR199","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314747121","volume":"121","author":"G Zhao","year":"2024","unstructured":"Zhao G, Xue L, Geisler HC, et\u00a0al. Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery. Proc Natl Acad Sci U S A. 2024;121(7):e2314747121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"956_CR200","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads2295","volume":"11","author":"C Fu","year":"2025","unstructured":"Fu C, Jin X, Ji K, et\u00a0al. Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice. Sci Adv. 2025;11(13):eads2295.","journal-title":"Sci Adv"},{"issue":"1","key":"956_CR201","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12951-025-03129-z","volume":"23","author":"YT Yen","year":"2025","unstructured":"Yen YT, Zhang Z, Chen A, et\u00a0al. Enzymatically responsive nanocarriers targeting PD-1 and TGF-\u03b2 pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy. J Nanobiotechnology. 2025;23(1):124.","journal-title":"J Nanobiotechnology"},{"issue":"6","key":"956_CR202","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002508","volume":"9","author":"M Sun","year":"2021","unstructured":"Sun M, Gu P, Yang Y, et\u00a0al. Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NF\u03baB axis. J Immunother Cancer. 2021;9(6):e002508.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"956_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13801-0","volume":"25","author":"Z Yin","year":"2025","unstructured":"Yin Z, Zhang H, Zhang K, et al. Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma. BMC Cancer. 2025;25(1):474. https:\/\/doi.org\/10.1186\/s12885-025-13801-0. (Published 2025 Mar 14).","journal-title":"BMC Cancer"},{"key":"956_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217935","volume":"631","author":"C Wang","year":"2025","unstructured":"Wang C, Han L, Zhang J, et\u00a0al. Radiotherapy in combination with PD-1 and TIGIT blockade mediate antitumor abscopal effects and immune memory via CD8+ T cells. Cancer Lett. 2025;631:217935. https:\/\/doi.org\/10.1016\/j.canlet.2025.217935.","journal-title":"Cancer Lett"},{"issue":"24","key":"956_CR205","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-6049","volume":"10","author":"NH Wang","year":"2022","unstructured":"Wang NH, Lei Z, Yang HN, et\u00a0al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann Transl Med. 2022;10(24):1406. https:\/\/doi.org\/10.21037\/atm-22-6049.","journal-title":"Ann Transl Med"},{"key":"956_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152711","volume":"786","author":"H Li","year":"2025","unstructured":"Li H, Kwon J, Kim HJ, Kim BH. Immune-modulatory effects of low-dose radiotherapy through macrophage polarization and transcriptional rewiring in triple-negative breast cancer. Biochem Biophys Res Commun. 2025;786:152711. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152711.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"956_CR207","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010960","volume":"13","author":"P Kalinski","year":"2025","unstructured":"Kalinski P, Kokolus KM, Gandhi S. Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy. J Immunother Cancer. 2025;13(5):e010960. https:\/\/doi.org\/10.1136\/jitc-2024-010960. (Published 2025 May 19).","journal-title":"J Immunother Cancer"},{"issue":"10","key":"956_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07074-x","volume":"15","author":"D Zhang","year":"2024","unstructured":"Zhang D, Wang M, Liu G, et\u00a0al. Novel FABP4+C1q+ macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK\/JAK\/STAT axis. Cell Death Dis. 2024;15(10):717. https:\/\/doi.org\/10.1038\/s41419-024-07074-x.","journal-title":"Cell Death Dis"},{"issue":"1","key":"956_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. https:\/\/doi.org\/10.1186\/s12943-019-0974-6. (Published 2019 Mar 30).","journal-title":"Mol Cancer"},{"issue":"606","key":"956_CR210","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1616","volume":"13","author":"A Martinez-Usatorre","year":"2021","unstructured":"Martinez-Usatorre A, Kadioglu E, Boivin G, et\u00a0al. Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Sci Transl Med. 2021;13(606):eabd1616. https:\/\/doi.org\/10.1126\/scitranslmed.abd1616.","journal-title":"Sci Transl Med"},{"issue":"46","key":"956_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202511152","volume":"12","author":"B Gao","year":"2025","unstructured":"Gao B, Wang Y, Sun Z, et\u00a0al. NQO1\/p65\/CXCL12 axis-recruited Tregs mediate resistance to anti-PD-1 plus lenvatinib therapy in PIVKA-II-positive hepatocellular carcinoma. Adv Sci (Weinh). 2025;12(46):e11152. https:\/\/doi.org\/10.1002\/advs.202511152.","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"956_CR212","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010812","volume":"13","author":"H Tang","year":"2025","unstructured":"Tang H, You T, Ge H, et al. Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC. J Immunother Cancer. 2025;13(9):e010812. https:\/\/doi.org\/10.1136\/jitc-2024-010812. (Published 2025 Sep 21).","journal-title":"J Immunother Cancer"},{"issue":"8","key":"956_CR213","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","volume":"12","author":"BC O\u2019Connell","year":"2024","unstructured":"O\u2019Connell BC, Hubbard C, Zizlsperger N, et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024;12(8):e009160. https:\/\/doi.org\/10.1136\/jitc-2024-009160. (Published 2024 Aug 30).","journal-title":"J Immunother Cancer"},{"issue":"4","key":"956_CR214","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1470-2045(24)00040-8","volume":"25","author":"BHL Goulart","year":"2024","unstructured":"Goulart BHL, Mushti SL, Chatterjee S, et\u00a0al. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis. Lancet Oncol. 2024;25(4):455\u201362.","journal-title":"Lancet Oncol"},{"key":"956_CR215","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.810472","volume":"9","author":"X Liu","year":"2022","unstructured":"Liu X, Qiao L. Hyperprogressive disease in malignant carcinoma with immune checkpoint inhibitor use: a review. Front Nutr. 2022;9:810472 (Published 2022 Mar 25).","journal-title":"Front Nutr"},{"issue":"7","key":"956_CR216","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, et\u00a0al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498\u2013512.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"956_CR217","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"956_CR218","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.462","volume":"11","author":"P Chen","year":"2021","unstructured":"Chen P, Wang Y, Li J, et\u00a0al. Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing. Clin Transl Med. 2021;11(6):e462.","journal-title":"Clin Transl Med"},{"issue":"5","key":"956_CR219","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217276","volume":"14","author":"T Affolter","year":"2019","unstructured":"Affolter T, Llewellyn HP, Bartlett DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE. 2019;14(5):e0217276 (Published 2019 May 21).","journal-title":"PLoS ONE"},{"issue":"1","key":"956_CR220","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41392-025-02143-9","volume":"10","author":"H Li","year":"2025","unstructured":"Li H, Chen X, Wang JJ, et\u00a0al. Spatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis. Signal Transduct Target Ther. 2025;10(1):59.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"956_CR221","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/gutjnl-2021-324339","volume":"71","author":"J Sheng","year":"2022","unstructured":"Sheng J, Zhang J, Wang L, et\u00a0al. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut. 2022;71(6):1176\u201391.","journal-title":"Gut"},{"key":"956_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1396719","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Z, Yuan J, Yu J, Chen D. Spatial interaction and functional status of CD68+SHP2+ macrophages in tumor microenvironment correlate with overall survival of NSCLC. Front Immunol. 2024;15:1396719. https:\/\/doi.org\/10.3389\/fimmu.2024.1396719. (Published 2024 May 10).","journal-title":"Front Immunol"},{"issue":"1","key":"956_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00963-0","volume":"9","author":"CW Tan","year":"2025","unstructured":"Tan CW, Berrell N, Donovan ML, et al. The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironment. npj Precis Oncol. 2025;9(1):191. https:\/\/doi.org\/10.1038\/s41698-025-00963-0. (Published 2025 Jun 18).","journal-title":"npj Precis Oncol"},{"issue":"7","key":"956_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.101018","volume":"24","author":"S Karagach","year":"2025","unstructured":"Karagach S, Smollich J, Atrakchi O, Mohan V, Geiger T. High-throughput single-cell proteomics of in vivo cells. Mol Cell Proteomics. 2025;24(7):101018. https:\/\/doi.org\/10.1016\/j.mcpro.2025.101018.","journal-title":"Mol Cell Proteomics"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00956-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:08:37Z","timestamp":1781651317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00956-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00956-2","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}